{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:03:33Z","timestamp":1791932613584,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6 (NCT03173092) enrolled transplant-ineligible patients with newly diagnosed MM to receive all-oral ixazomib-lenalidomide-dexamethasone (IRd; \u226439 cycles or until progression or toxicity) following three cycles of bortezomib-based induction. Primary endpoint: 2-year progression-free survival (PFS). Key secondary\/exploratory endpoints included overall response rate (ORR), overall survival (OS), safety, quality of life (QoL), treatment satisfaction, and actigraphy. At datacut, in the fully accrued cohort of 140 patients, median age was 73 years with 42% aged \u226575 and 61% deemed frail; 10% of patients were ongoing on treatment. After a median follow-up of 27 months, the 2-year PFS rate was 71% (95% confidence interval: 61\u201378). ORR increased from 62% at the end of induction to 80% following <jats:italic>in-<\/jats:italic>class transition (<jats:italic>i<\/jats:italic>CT) to IRd for a median of 11 months. The 2-year OS rate was 86%. The overall safety profile\/actigraphy levels were consistent with previous reports; QoL\/treatment satisfaction scores were stable with ongoing therapy. <jats:italic>i<\/jats:italic>CT to IRd may allow prolonged PI-based therapy with promising efficacy and a tolerable safety profile, while maintaining QoL.<\/jats:p>","DOI":"10.1038\/s41408-023-00912-9","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T09:02:27Z","timestamp":1695114147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saulius K.","family":"Girnius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Noga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruemu E.","family":"Birhiray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Manda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habte A.","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Presley","family":"Whidden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"912_CR1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.23933","volume":"90","author":"MV Mateos","year":"2015","unstructured":"Mateos MV, Richardson PG, Dimopoulos MA, Palumbo A, Anderson KC, Shi H, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90:314\u20139.","journal-title":"Am J Hematol"},{"key":"912_CR2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-016-2901-x","volume":"96","author":"VH Jimenez-Zepeda","year":"2017","unstructured":"Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Ann Hematol. 2017;96:431\u20139.","journal-title":"Ann Hematol"},{"key":"912_CR3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet."},{"key":"912_CR4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med. 2008;359:906\u201317.","journal-title":"New Engl J Med"},{"key":"912_CR5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","volume":"31","author":"JF San Miguel","year":"2012","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2012;31:448\u201355.","journal-title":"J Clin Oncol"},{"key":"912_CR6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BG Durie","year":"2020","unstructured":"Durie BG, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:53.","journal-title":"Blood Cancer J"},{"key":"912_CR7","unstructured":"Velcade\u00ae Prescribing Information. 2022. https:\/\/www.velcade.com\/files\/pdfs\/VELCADE_PRESCRIBING_INFORMATION.pdf. Accessed 01 March 2023."},{"key":"912_CR8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksa\u00e7 M, Wen P, Jongen J, Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26:595\u2013608.","journal-title":"Leukemia."},{"key":"912_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29:315\u201321.","journal-title":"Curr Opin Oncol"},{"key":"912_CR10","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos M-V. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9:26.","journal-title":"Blood Cancer J"},{"key":"912_CR11","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11:40.","journal-title":"Blood Cancer J"},{"key":"912_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:1\u201312.","journal-title":"Blood Cancer J"},{"key":"912_CR13","doi-asserted-by":"crossref","first-page":"844779","DOI":"10.3389\/fonc.2022.844779","volume":"12","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Bertuglia G, Oliva S. Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. Front Oncol. 2022;12:844779.","journal-title":"Front Oncol"},{"key":"912_CR14","unstructured":"Ninlaro\u00ae Prescribing Information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/208462lbl.pdf. Accessed 01 March 2023."},{"key":"912_CR15","unstructured":"Ninlaro\u00ae Summary of Product Characteristics. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ninlaro-epar-product-information_en.pdf. Accessed 01 March 2023."},{"key":"912_CR16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med. 2016;374:1621\u201334.","journal-title":"New Engl J Med"},{"key":"912_CR17","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137:3616\u201328.","journal-title":"Blood."},{"key":"912_CR18","doi-asserted-by":"crossref","first-page":"e910","DOI":"10.1016\/j.clml.2020.06.024","volume":"20","author":"S Manda","year":"2020","unstructured":"Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, et al. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clin Lymphoma Myeloma Leuk. 2020;20:e910\u2013e925.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"912_CR19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587.","journal-title":"J Clin Oncol"},{"key":"912_CR20","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33:3921\u20139.","journal-title":"J Clin Oncol"},{"key":"912_CR21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15:1503\u201312.","journal-title":"Lancet Oncol"},{"key":"912_CR22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen W-M, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia."},{"key":"912_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","volume":"103","author":"K Sully","year":"2019","unstructured":"Sully K, Trigg A, Bonner N, Moreno-Koehler A, Trennery C, Shah N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ\u2010MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103:500\u20139.","journal-title":"Eur J Haematol"},{"key":"912_CR24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant\u2010ineligible multiple myeloma. Br J Haematol. 2018;182:222\u201330.","journal-title":"Br J Haematol"},{"key":"912_CR25","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2019-128000","volume":"134","author":"EK O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell EK, Laubach JP, Yee AJ, Redd R, Huff CA, Basile F, et al. Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma. Blood. 2019;134:3178.","journal-title":"Blood."},{"key":"912_CR26","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta J-J, Paiva B, Vidriales M-B, Cord\u00f3n L, Cedena M-T, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35:2900.","journal-title":"J Clin Oncol"},{"key":"912_CR27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.clml.2022.05.003","volume":"22","author":"AY Naser","year":"2022","unstructured":"Naser AY, Ofori-Asenso R, Al Awawdeh S, Qadus S, Alwafi H, Liew D. Real world adherence to and persistence with oral oncolytics in multiple myeloma: A systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2022;22:760\u201337.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"912_CR28","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1182\/blood-2022-159807","volume":"140","author":"S Hentzen","year":"2022","unstructured":"Hentzen S, Meirson T, Koehn K, Goodman AM, Chakraborty R, Prasad V, et al. Attrition and withdrawal amongst patients with multiple myeloma participating in randomized clinical trials: A systematic review. Blood. 2022;140:7950\u20131.","journal-title":"Blood"},{"key":"912_CR29","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39:2430\u201342.","journal-title":"J Clin Oncol"},{"key":"912_CR30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","volume":"34","author":"EA Coleman","year":"2011","unstructured":"Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, et al. Fatigue, sleep, pain, mood and performance status in patients with multiple myeloma. Cancer Nurs. 2011;34:219\u201327.","journal-title":"Cancer Nurs"},{"key":"912_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5868-8-1","volume":"8","author":"C Tudor-Locke","year":"2011","unstructured":"Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B, et al. How many steps\/day are enough? For adults. Int J Behav Nutr Phys Act. 2011;8:1\u201317.","journal-title":"Int J Behav Nutr Phys Act"},{"key":"912_CR32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","volume":"17","author":"JJ Shah","year":"2017","unstructured":"Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:575\u201383.e572.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"912_CR33","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2017.03.101","volume":"17","author":"M Fiala","year":"2017","unstructured":"Fiala M, Dukeman J, Stockerl-Goldstein K, Tomasson M, Wildes T, Vij R. The real-world characteristics and outcomes of newly diagnosed myeloma patients ineligible for clinical trials. Clin Lymphoma Myeloma Leuk. 2017;17:e55\u2013e56.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"912_CR34","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2019-125749","volume":"134","author":"VT Hungria","year":"2019","unstructured":"Hungria VT, Lee HC, Abonour R, Rifkin RM, Terpos E, Leleu X, et al. Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood. 2019;134:1887.","journal-title":"Blood."},{"key":"912_CR35","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD. 2020."},{"key":"912_CR36","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.lana.2022.100252","volume":"11","author":"BE Turner","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: A cohort study. The Lancet Regional Health - Americas. 2022;11:100252.","journal-title":"The Lancet Regional Health - Americas"},{"key":"912_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:8\u201317.e16.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"912_CR38","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2217\/fon-2020-1225","volume":"17","author":"R H\u00e1jek","year":"2021","unstructured":"H\u00e1jek R, Mina\u0159\u00edk J, Straub J, Pour L, Jungova A, Berdeja JG, et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed\/refractory multiple myeloma. Future Oncol. 2021;17:2499\u2013512.","journal-title":"Future Oncol"},{"key":"912_CR39","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00277-020-04234-9","volume":"99","author":"J Li","year":"2020","unstructured":"Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, et al. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020;99:2589\u201398.","journal-title":"Ann Hematol"},{"key":"912_CR40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","volume":"33","author":"SK Kumar","year":"2019","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019;33:1736\u201346.","journal-title":"Leukemia."},{"key":"912_CR41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-136293","volume":"136","author":"S Bringhen","year":"2020","unstructured":"Bringhen S, Pour L, Benjamin R, Grosicki S, Min C-K, De Farias DLC, et al. Progression-free survival (PFS) benefit demonstrated and quality of life (QoL) maintained across age and frailty subgroups with the oral proteasome inhibitor (PI) ixazomib vs placebo as post-induction maintenance therapy in non-transplant newly diagnosed multiple myeloma (NDMM) patients (Pts): analysis of the TOURMALINE-MM4 phase 3 trial. Blood. 2020;136:30\u201331.","journal-title":"Blood."},{"key":"912_CR42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.HS9.0000846656.55700.df","volume":"6","author":"RM Rifkin","year":"2022","unstructured":"Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, et al. P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). HemaSphere. 2022;6:837\u20138.","journal-title":"HemaSphere"},{"key":"912_CR43","unstructured":"FDA. Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry - DRAFT GUIDANCE. 2022. https:\/\/www.fda.gov\/media\/157635\/download. Accessed 15 March 2023."},{"key":"912_CR44","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000507690","volume":"143","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematol. 2020;143:410\u20136.","journal-title":"Acta Haematol"},{"key":"912_CR45","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/S2352-3026(20)30124-1","volume":"7","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol. 2020;7:e435\u2013e437.","journal-title":"Lancet Haematol"},{"key":"912_CR46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.htct.2020.05.001","volume":"42","author":"V Hungria","year":"2020","unstructured":"Hungria V, Garnica M. Cruso\u00e9 EdQ, Magalhaes Filho RJPd, Martinez G, Bittencourt R, et al. Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel-ABHH monoclonal gammopathies committe. Hematol Transfus Cell Ther. 2020;42:200\u20135.","journal-title":"Hematol Transfus Cell Ther"},{"key":"912_CR47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(20)30204-7","volume":"21","author":"B You","year":"2020","unstructured":"You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020;21:619\u201321.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00912-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T17:03:57Z","timestamp":1700499837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00912-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00912-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RMR: Member of board of directors\/advisory committee: Amgen, Bristol Myers Squibb (Celgene), Coherus, Fresenius-Kabi, Sanofi, Takeda, and Karyopharm; Current employee and equity holder: McKesson. SKG: Honoraria: BMS, Genentech, and GSK; Speakers bureau: BMS, Celgene, GSK, Takeda, and Beigene; Member of board of directors\/advisory committee: Takeda. SJN: Current employee: Takeda. REB: Consultancy: Alexion, AbbVie, Novartis, Janssen, Pharmacyclics, and Puma; Honoraria: AbbVie, Novartis, Bayer, Seattle Genetics, Coheris, Kyte Pharma, Celgene, Helsin, and Amgen; Research funding: Puma, Takeda, and Incyte; Speakers bureau: Novartis, Janssen, Pharmacyclics, Puma, Takeda, Incyte, Amgen, Pfizer, BMS, Tessaro, AstraZeneca, Genomic Health, Sanofi, Clovis, Exelexis, and Lilly. SK: nothing to disclose. S.M.: Honoraria: Morphosys; Current equity holder: Genmab. RML: nothing to disclose. HAY: Speakers bureau: Karyopharm, AstraZeneca, Janssen, Beigene, GSK, Sanofi, Amgen, Pharmacyclics, and Takeda; Current stockholder: Karyopharm; Current employee: Texas Oncology. DC: Current employee: Takeda; Ownership of stock\/shares with Takeda. EL: Current employee: Takeda. PW: Current employee: Takeda. JR: Consulting fees from Takeda and BMS\/Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}